Trial reportNature2024
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
3 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 122 papers.
0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed
27.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Combined Treatment With Cemiplimab (Anti-PD-1) and Dupilumab (Anti-IL-4R) in Patients With Early-stage, Resectable NSCLC
NCT07281716 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation
A Phase 1b/2 Study of Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
A Phase 2 Trial of Nadunolimab for Current or Former Smokers With High-risk Lung Nodules.
Who cites it
122 citing papers in PubMed, 166 citations in OpenAlex.
- Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.Signal transduction and targeted therapy · 2025Trial
- Predicting PD-L1 + CD8 - status in non-small cell lung cancer tissue from clinical indicators using machine learning.Chinese medical journal · 2026Article
- Cytotoxic CD4Nature aging · 2026Article
- Basophil Extracellular Traps in Immunity and Disease.Cancers · 2026Review
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Collaborative functionality between three types of inflammation in idiopathic pulmonary fibrosis.Nature immunology · 2026Review
- Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging.Immunity · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Therapeutic repurposing of old drugs to modulate the tumor immune microenvironment and enhance immunotherapy efficacy.Journal of pharmaceutical analysis · 2026Review
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- IL4I1+ macrophages drive hepatocellular carcinoma progression by responding to biomechanical cues.JHEP reports : innovation in hepatology · 2026Article
- Platelet-macrophage cooperation drives IL-33-dependent type 2 lung immunopathology in a sex-biased manner.The Journal of allergy and clinical immunology · 2026Article
- Basophils drive the resolution and promote wound healing in adult and aged mice.The Journal of experimental medicine · 2026Article
- Harnessing myeloid cell plasticity for cancer therapy.Nature cancer · 2026Review
- Article
- Macrophage-intrinsic and IL-9-dependent arginine metabolism promotes lung tumor growth.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- An ontogeny-cytokine code determines macrophage response polarity and tumor outcomes.Communications biology · 2026Article
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline.Nature biomedical engineering · 2026Article
62 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
38 authors at 8 institutions in 6 countries.
Nelson M LaMarcheMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samarth Hegde *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Matthew D Park *Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Barbara B MaierMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Leanna TroncosoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-2529-9267
Jessica Le BerichelMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pauline HamonMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6776-1635
Meriem BelabedMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raphaël MattiuzMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3292-1635
Clotilde HennequinMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Theodore ChinMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Amanda M ReidMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Iván Reyes-TorresMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Erika NemethMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ruiyuan ZhangColumbia Stem Cell Initiative, Department of Genetics and Development, Columbia University, New York, NY, USA.
Oakley C OlsonColumbia Stem Cell Initiative, Department of Genetics and Development, Columbia University, New York, NY, USA.
Deborah B DoroshowThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicholas C RohsThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jorge E GomezThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rajwanth VeluswamyThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicole HallThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Nicholas VenturiniMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3769-5956
Florent GinhouxSingapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), BIOPOLIS, Singapore, Singapore.ORCID 0000-0002-2857-7755
Zhaoyuan LiuShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mark BuckupMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Igor FigueiredoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vladimir RoudkoMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kensuke MiyakeInflammation, Infection and Immunity Laboratory, Advanced Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.ORCID 0000-0003-1149-3755
Hajime KarasuyamaInflammation, Infection and Immunity Laboratory, Advanced Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.ORCID 0000-0003-0689-0836
Edgar Gonzalez-KozlovaMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-6948-0626
Sacha GnjaticMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-5643-9520
Emmanuelle PasseguéColumbia Stem Cell Initiative, Department of Genetics and Development, Columbia University, New York, NY, USA.ORCID 0000-0002-3516-297X
Seunghee Kim-SchulzeMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Brian D BrownMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3670-8778
Fred R HirschThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Brian S KimMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-8100-7161
Thomas U MarronMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0001-5903-8191
Miriam MeradMarc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. miriam.merad@mssm.edu.ORCID 0000-0002-4481-7827
Icahn School of Medicine at Mount Sinai · USColumbia University · USTokyo Medical and Dental University · JPAgency for Science, Technology and Research · SGAllen Institute for Brain Science · USAustrian Academy of Sciences · ATShanghai Jiao Tong University · CNTisch Hospital · US
Funding
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Deanna L Benson · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MERK control of Dendritic Cell Differentiation, Homeostasis and DiseaseR01CA154947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CARL E ALLEN, MIRIAM MERAD · 2011 to 2026
$7.0MMount Sinai Medical Scientist Training ProgramT32GM146636 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Talia H Swartz · 2022 to 2026
$6.8MThe PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3MSpatial functional genomics to identify regulators of the tumor microenvironment and cancer immunityU01CA282114 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2023 to 2026
$4.2MInvestigating Macrophage Molecular and Functional Diversity in Tumor ImmunityR01CA254104 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BROWN, BRIAN D, MERAD, MIRIAM · 2021 to 2025
$3.4MDissecting the pathways driving progenitor to pro-tumor macrophage programmingR01CA257195 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Brian D Brown, MIRIAM MERAD · 2021 to 2026
$3.3MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MBig Omics Data Engine 2 SupercomputerS10OD026880 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2019 to 2019
$2.0MPRIMAVO: Interactive exploration of cancer patient precision immune monitoring data in clinical trialsR33CA263705 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GUMUS, ZEYNEP HULYA · 2021 to 2021
$1.5MNCI NIH HHS K00 CA223043NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA154947NCI NIH HHS R01 CA254104NCI NIH HHS R01 CA257195NCI NIH HHS R33 CA263705NCI NIH HHS U01 CA282114NCI NIH HHS U24 CA224319NICHD NIH HHS R33 HD105593NIDDK NIH HHS U01 DK124165NIGMS NIH HHS T32 GM146636NIH HHS S10 OD026880NIH HHS S10 OD030463
Abstract
Myeloid cells are known to suppress antitumour immunity
Indexed as
Bone MarrowCarcinogenesisInterleukin-4MyelopoiesisSignal TransductionAnimalsAntibodies, Monoclonal, HumanizedB7-H1 AntigenCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsInterleukin-4 Receptor alpha SubunitLung NeoplasmsLymphocytes, Tumor-InfiltratingMiceAntibodies, Monoclonal, HumanizedB7-H1 AntigendupilumabIL4 protein, humanIl4 protein, mouseIl4ra protein, mouseImmune Checkpoint InhibitorsInterleukin-4Interleukin-4 Receptor alpha SubunitProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.